Shop legal, local weed.


Congress passes ‘Cannabidiol and Marihuana Research Expansion Act’

Published on April 4, 2022
Congress may finally allow faster CBD drug development. This sclerotic pace of reform is why people want to end the filibuster.(smartboy10,channarongsds/iStock)
Congress may finally allow faster CBD drug development. This sclerotic pace of reform is why people want to end the filibuster.(smartboy10,channarongsds/iStock)

Tens of millions of medical patients who could benefit from new, FDA-approved prescription CBD got the tiniest of breaks from Congress Monday.

The US House of Representatives voted this evening to pass the Cannabidiol and Marihuana Research Expansion Act, which is intended to allow new drug research and development. The Senate voted unanimously to pass the bill in March.

Doctors have reported for decades that marijuana’s federal Schedule I status—designating it as a drug as dangerous as heroin—blocks basic drug trials. A generation of patients has undertaken those trials on themselves. (Ninety-two percent of medical cannabis users reported efficacy in one state survey in 2014.)

Currently, 38 states have legalized cannabis medically or for all adults, yet ‘marijuana’ remains a Schedule I substance.

The new Act—sponsored by Sen. Dianne Feinstein (D-CA), Sen. Chuck Grassley (R-IA), and eight other senators—doesn’t change weed’s Schedule I status. But it does force the federal government to allow more researchers to grow medical cannabis, and allows doctors to talk about pot without fear of losing their medical license, as well as other modest tweaks.

About 91% of Americans support medical marijuana legalization, Pew Research finds. Yet the CBD research expansion act came up for a vote, passed and then died in 2020.

The House of Representatives also passed a full-scale legalization bill—the MORE Act—last week.

About 68% of Americans support full legalization. But Sen. Feinstein—a long-serving Democrat representing the largest legal cannabis market on the planet, which did $5.1 billion in legal sales last year—is focused on further research, not legalizing it federally.

The Dianne Feinstein Mystery: Why Is She California’s Last Prohibitionist?

“Current rules and regulations make it hard for researchers to study how marijuana and marijuana-derived medications can best be used to treat various conditions,” said Sen. Feinstein, in a release. “This important legislation will cut the red tape around the research process, helping get FDA-approved, marijuana-derived medications safely to patients.”

Policy experts note that marijuana has been studied for decades, and has shown medical efficacy, with a lower abuse profile than prescription drugs. And yet Republican Sen. Grassley cheered the chance for more such research in a release.

Congress just legalized marijuana via the MORE Act—again.

“This bipartisan bill is critical to better understanding the marijuana plant and its potential benefits and side effects,” Grassley said in a statement. “It will empower the FDA to analyze CBD and medical marijuana products in a safe and responsible way so that the American public can decide whether to utilize them in the future based on sound scientific data. Researching marijuana is widely supported by my colleagues on both sides of the aisle, and it’s a smart step forward in addressing this current Schedule I drug.”

Shop highly rated dispensaries near you

Showing you dispensaries near
See all dispensaries
David Downs
David Downs
Leafly Senior Editor David Downs is the former Cannabis Editor of the San Francisco Chronicle. He's appeared on The Today Show, and written for Scientific American, The New York Times, WIRED, Rolling Stone, The Onion A/V Club, High Times, and many more outlets. He is a 2023 judge for The Emerald Cup, and has covered weed since 2009.
View David Downs's articles
Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.